NYSE · Healthcare
Arcus Biosciences, Inc. (RCUS)
As-reported financials and recent SEC filings for Arcus Biosciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$247.0M
Net income
$-353.0M
Net margin
-142.9%
Diluted EPS
$-3.29
ROE
-55.9%
P/E (TTM)
—
Market cap
$3.90B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-386.0M | $-330.0M | $-340.0M | $-280.0M | $54.0M |
| Net income | $-353.0M | $-283.0M | $-307.0M | $-267.0M | $53.0M |
| Diluted EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-24
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →8-K2026-06-12
View on EDGAR →Go deeper on RCUS
Search Arcus Biosciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.